"Recommendation GUID","Guideline GUID","Full Guideline title","Rec ID (Full)","NICE Guideline title","Rec ID (NICE)","Recommendation body","Recommendation title","Rec Grade Code","Set ID","","Type","","","","","","","","","","","",""
"CG73R1.1.1","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R1","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.1","Whenever a request for serum creatinine measurement is made, clinical 
laboratories should report an estimate of glomerular filtration rate (eGFRcreatinine) using a prediction equation (see recommendation 1.1.2) in 
addition to reporting the serum creatinine result.","GFR estimate with prediction equation","","CG73S2","","","","","","","","","","","","","",""
"CG73R1.1.2","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R2","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care update","R1.1.2","Clinical laboratories should: 
 use the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
creatinine equation to estimate GFR creatinine, using creatinine assays with calibration traceable to standardised reference material 
 use creatinine assays that are specific (for example, enzymatic assays) and zero-biased compared with isotope dilution mass spectrometry (IDMS) 
 participate in the UK National External Quality Assessment Service scheme for creatinine. [new 2014] 
","Estimation of GFR creatinine","","CG73S2","","","","","","","","","","","","","",""
"CG73R1.1.3","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R3","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care update","R1.1.3","Apply a correction factor to GFR values estimated using the CKD-EPI creatinine equation for people of African–Caribbean or African family origin (multiply eGFR by 1.159). [new 2014] 
","GFR values and correction factor application","","CG73S2","","","","","","","","","","","","","",""
"CG73R1.1.4","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R4","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care update","R1.1.4","In people with extremes of muscle mass – for example, in bodybuilders, people who have had an amputation or people with  muscle wasting disorders – interpret eGFRcreatinine with caution. (Reduced muscle mass will lead to overestimation and increased  muscle mass to underestimation of the GFR.) 
","interpretation of eGFR creatinine results for those with extremes of muscle mass","","CG73S1","","","","","","","","","","","","","",""
"CG73R1.1.5","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R5","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care update","R1.1.5","Advise people not to eat any meat in the 12 hours before having a blood test for eGFRcreatinine. Avoid delaying the despatch of blood samples to ensure that they are received and processed by  the laboratory within 12 hours of venepuncture. [2008] 
","eFGR creatinine test and meat consumption","","CG73S1","","","","","","","","","","","","","",""
"CG73R1.1.6","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R6","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care update","R1.1.6","Whenever a request for serum cystatin C measurement is made, clinical 
laboratories should report an estimate of glomerular filtration rate 
(eGFRcystatinC) using a prediction equation (see recommendation 5) in 
addition to reporting the serum cystatin C result. [new 2014] 
","glomerular filtration rate estimation","","CG73S1","","","","","","","","","","","","","",""
"CG73R1.1.7","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R7","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care update","R1.1.7","When an improved assessment of risk is needed (see recommendation 
15), clinical laboratories should use the CKD-EPI cystatin C equation to 
estimate GFRcystatinC. [new 2014] 
","use of CKD-EPI cystatin C equation","","CG73S1","","","","","","","","","","","","","",""
"CG73R1.1.8","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R8","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care update","R1.1.8","Clinical laboratories should use cystatin C assays calibrated to the 
international standard to measure serum cystatin C for cystatin C-based 
estimates of GFR. [new 2014] 
","Calibration of cystatin C assays","","CG73S1","","","","","","","","","","","","","",""
"CG73R1.1.9","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R9","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care update","R1.1.9"," Interpret eGFRcystatinC with caution in people with uncontrolled thyroid disease as eGFRcystatinC values may be falsely elevated in people with hypothyroidism and reduced in people with  hyperthyroidism. [new 2014] 
","eGFR cystatin C results in those with uncontrolled thyroid disease","","CG73S1","","","","","","","","","","","","","",""
"CG73R1.1.10","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R10","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.10","Clinical laboratories should report GFR either as a whole number if it is 
90 ml/min/1.73 m or less, or as ‘greater than 90 ml/min/1.73 m [new 
2014] ","Reporting GFR as whole number","","CG73S1","","","","","","","","","","","","","",""
"CG73R1.1.11","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R11","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.11","If GFR is greater than 90 ml/min/1.73 m use an increase in serum creatinine concentration of more than 20% to infer significant reduction in renal function. [new 2014] 
","Inferring reduction in renal function","","CG73S1","","","","","","","","","","","","","",""
"CG73R1.1.12","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R12","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.12","Interpret reported values of eGFR ≥60 ml/min/1.73m2with caution, bearing in mind that estimates of GFR become less accurate as the true GFR increases.","Interpreting with caution","","CG73S1","","","","","","","","","","","","","",""
"CG73R1.1.13","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R13","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.13","Confirm an eGFR result of less than 60 ml/min/1.73 m in a person not previously tested by repeating the test within 2 weeks. Allow for biological and analytical variability of serum creatinine (±5%) when interpreting changes in eGFR. [2008] 
","Confirmation of low eGFR result","","CG73S1","","","","","","","","","","","","","",""
"CG73R1.1.14","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R14","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.14","Consider using eGFRcystatinC to confirm the diagnosis of CKD in people with: 
 an eGFRcreatinine of 45–59 ml/min/1.73 m2, sustained for at least 90 days and 
 no proteinuria (albumin:creatinine ratio [ACR] less than 3 mg/mmol).","Confirmation of CKD","","CG73S1","","","","","","","","","","","","","",""
"CG73R1.1.15","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R15","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.15","Do not diagnose CKD in people with: 
 an eGFRcreatinine of 45–59 ml/min/1.73 m2 and 
 an eGFRcystatinC of more than 60 ml/min/1.73 m2 and 
 no other marker of kidney disease7. [new 2014] 
","When not to diganose CKD","","CG73S1","","","","","","","","","","","","","",""
"CG73R1.1.16","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R16","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.16","Where a highly accurate measure of GFR is required – for example, during monitoring of chemotherapy and in the evaluation of renal function in potential living donors – consider a reference standard measure (inulin, 51Cr-EDTA, 125I-iothalamate or iohexol). [2008] 
","Reference standard measures where highly accurate eGFR required","","CG73S1","","","","","","","","","","","","","",""
"CG73R1.1.17","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R17","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.17","Do not use reagent strips to identify proteinuria unless they are capable of specifically measuring albumin at low concentrations and expressing the result as an ACR .","Use of  reageant strips to identify proteinuria","","CG73S3","","","","","","","","","","","","","",""
"CG73R1.1.18","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R18","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.18","To detect and identify proteinuria, use urine albumin:creatinine ratio (ACR) in preference, as it has greater sensitivity than protein:creatinine ratio (PCR) for low levels of proteinuria. For quantification and monitoring of proteinuria, PCR can be used as an alternative. ACR is the recommended method for people with diabetes.","Use of ACR to detect proteinuria","","CG73S3","","","","","","","","","","","","","",""
"CG73R1.1.19","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R19","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.19","For the initial detection of proteinuria, if the ACR is 30 mg/mmol or more (this is approximately equivalent to PCR 50 mg/mmol or more, or a urinary protein excretion 0.5 g/24 h or more) and less than 70 mg/mmol (approximately equivalent to PCR less than 100 mg/mmol, or urinary protein excretion less than 1 g/24 h) this should be confirmed by a subsequent early morning sample. If the initial ACR is 70 mg/mmol or more, or the PCR 100 mg/mmol or more, a repeat sample need not be tested","Initial detection of proteinuria","","CG73S3","","","","","","","","","","","","","",""
"CG73R1.1.20","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R20","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.20","Regard a confirmed ACR of 3 mg/mmol or more as clinically  important proteinuria.","Clinically important proteinuria level","","CG73S3","","","","","","","","","","","","","",""
"CG73R1.1.20","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R20","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.20","Regard a confirmed ACR of 3 mg/mmol or more as clinically  important proteinuria.","Clinically important proteinuria level","","","","","","","","","","","","","","","",""
"CG73R1.1.20","CG73","","","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.20","Regard a confirmed ACR of 3 mg/mmol or more as clinically  important proteinuria.","Clinically important proteinuria level","","","","","","","","","","","","","","","",""
"CG73R1.1.21","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R21","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.21","Quantify urinary albumin or urinary protein loss as in recommendation 1.1.18 for: 
 people with diabetes 
 people without diabetes with a GFR less than 60 ml/min/1.73 m2. 
[2008, amended 2014] ","Quantification of urinary albumin or urinary protein loss","","CG73S3","","","","","","","","","","","","","",""
"CG73R1.1.22","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R22","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.22","Quantify by laboratory testing the urinary albumin or urinary protein loss of people with a GFR of 60 ml/min/1.73 m2 or more if there is a strong suspicion of CKD (see also recommendation 1.1.28). [2008] ","When to quantify urinary albumin or urinary protein loss","","CG73S3","","","","","","","","","","","","","",""
"CG73R1.1.23","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R23","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.23","When testing for the presence of haematuria, use reagent strips rather than urine microscopy.
● Evaluate further if there is a result of 1+ or more. 
● Do not use urine microscopy to confirm a positive result","Use of reagent strips for presence of haematuria","","CG73S3","","","","","","","","","","","","","",""
"CG73R1.1.24","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R24","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.24","When there is the need to differentiate persistent invisible haematuria in the absence of proteinuria from transient haematuria, regard 2 out of 3 positive reagent strip tests as confirmation of persistent invisible haematuria. ","Confirmation of persistent invisible haematuria","","CG73S3","","","","","","","","","","","","","",""
"CG73R1.1.25","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R25","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.25","Persistent invisible haematuria, with or without proteinuria, should prompt investigation for urinary tract malignancy in appropriate age groups.","Investigation for urinary tract malignancy","","CG73S3","","","","","","","","","","","","","",""
"CG73R1.1.26","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R26","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.26","Persistent invisible haematuria in the absence of proteinuria should be followed up annually with repeat testing for haematuria (see recommendations 1.1.24 and 1.1.25), proteinuria or albuminuria, GFR and blood pressure monitoring as long as the haematuria persists. [2008] 
","Follow up of persistent invisible haematuria","","","","","","","","","","","","","","","",""
"CG73R1.1.27","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R27","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.27","Monitor glomerular filtration rate (GFR) in people prescribed drugs known to be
nephrotoxic, such as calcineurin inhibitors and lithium. Check GFR at least annually in
people receiving long-term systemic non-steroidal anti-inflammatory drug (NSAID)
treatment","Monitoring of glomerular filtration rate","","CG73S7","","","","","","","","","","","","","",""
"CG73R1.1.28","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R28","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.28","Offer people testing for CKD if they have any of the following risk factors: 
diabetes 
 hypertension 
 acute kidney injury (see recommendation 1.3.8) 
 cardiovascular disease (ischaemic heart disease, chronic heart failure, peripheral vascular disease or cerebral vascular disease) 
 structural renal tract disease, renal calculi or prostatic hypertrophy 
 multisystem diseases with potential kidney involvement - for example, systemic lupus erythematosus 
 family history of stage 5 CKD or hereditary kidney disease 
 opportunistic detection of haematuria. [new 2014]
 
","When to offer testing for CKD","","CG73S7","","","","","","","","","","","","","",""
"CG73R1.1.29","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R29","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.29","Do not use age, gender or ethnicity as risk markers to test people for CKD. In the absence of metabolic syndrome, diabetes or hypertension, do not use obesity alone as a risk marker to test people for CKD. [2008, amended 2014] 
","Risk markers and CKD","","CG73S7","","","","","","","","","","","","","",""
"CG73R1.2.1","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R30","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.2.1","Classify CKD using a combination of GFR and ACR categories (as described in table 1). Be aware that: 
 increased ACR is associated with increased risk of progression 
 decreased GFR is associated with increased risk of progression 
 increased ACR and decreased GFR in combination multiply the risk of progression. [new 2014] 
","Classification of CKD","","CG73S7","","","","","","","","","","","","","",""
"CG73R1.2.2","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R31","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.2.2","For any given stage of CKD, do not determine management solely  by age. [new 2014] 
","Management of CKD and age","","CG73S7","","","","","","","","","","","","","",""
"CG73R1.2.3","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R32","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.2.3","After an informed discussion with the person with CKD, agree a plan to establish the cause (for example urinary tract obstruction,  nephrotoxic drugs or glomerular disease). [new 2014] 
","Discussion to establish cause of CKD","","CG73S8","","","","","","","","","","","","","",""
"CG73R1.2.4","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R33","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.2.4","Use the person’s GFR and ACR categories (see table 1) to indicate their risk of adverse outcomes (for example, CKD progression, acute kidney injury, all-cause mortality and cardiovascular events)  and discuss this with them. [new 2014] 
","Discussion of risk of adverse outcomes","","","","","","","","","","","","","","","",""
"CG73R1.2.5","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R34","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.2.5","Offer a renal ultrasound to all people with CKD who: 
 have progressive CKD (a sustained decrease in GFR of 25% or more and a change in GFR category, or a sustained decrease in GFR of 15 ml/min/1.73 m2 or more) 
 have visible or persistent invisible haematuria 
 have symptoms of urinary tract obstruction 
 have a family history of polycystic kidney disease and are aged over 20 years 
 have stage 4 or 5 CKD 
 are considered by a nephrologist to require a renal biopsy. [2008, amended 2014]","When to offer renal ultrasound","","CG73S5","","","","","","","","","","","","","",""
"CG73R1.2.6","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R35","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.2.6","Advise people with a family history of inherited kidney disease about the implications of an abnormal result before a renal ultrasound scan is arranged for them.","Family history and CKD","","CG73S5","","","","","","","","","","","","","",""
"CG73R1.1.16","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R16","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.1.16","All people with diabetes, and people without diabetes with a GFR less than 60 ml/min/1.73 m2, should have their urinary albumin/protein excretion quantified. The first abnormal result should be confirmed on an early morning sample (if not previously obtained).","Quantifiction of urinary albumin/protein excretion","","CG73S4","","","","","","","","","","","","","",""
"CG73R1.5.1","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R27","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.5.1","Take the following steps to identify progressive CKD:
● Obtain a minimum of three glomerular filtration rate (GFR) estimations over a period of not less than 90 days.
● In people with a new finding of reduced eGFR, repeat the estimated glomerular filtration rate (eGFR) within 2 weeks to exclude causes of acute deterioration of GFR, e.g. acute kidney injury or initiation of ACEI/ARB therapy ● Define progression as a decline in eGFR of >5 ml/min/1.73 m2 within one year, or
>10 ml/min/1.73 m2 within 5 years
● Focus particularly on those in whom a decline of GFR continuing at the observed rate would lead to the need for renal replacement therapy within their lifetime by extrapolating the current rate of decline.

","Identification of progressive CKD","","CG73S9","","","","","","","","","","","","","",""
"CG73R1.3.7","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R29","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.3.7","In people with CKD the chronic use of NSAIDs may 
be associated with progression and acute use is associated with a reversible decrease in GFR. Exercise caution when treating people with CKD with NSAIDs over prolonged periods of time. Monitor the effects on GFR, particularly in people with a low baseline GFR and/or in the presence of other risks for progression.","Progression and chronic use of NSAIDS","","CG73S10","","","","","","","","","","","","","",""
"CG73R1.7.1","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R64","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.7.1","Do not routinely measure calcium, phosphate, parathyroid hormone (PTH) and vitamin D levels  in people with stage 1, 2, 3a or 3b CKD.","Masurement in people with stage 1,2,3a,3b CKD","","CG73S11","","","","","","","","","","","","","",""
"CG73R1.7.2","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R65","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.7.2","Measure serum calcium, phosphate and PTH concentrations in people with stage 4 or 5 CKD (GFR less than 30 ml/min/1.73 m2 Determine the subsequent frequency of testing by the measured values and the clinical circumstances. Where doubt exists seek specialist opinion. ","Measurement in people with stage 4 or 5","","CG73S11","","","","","","","","","","","","","",""
"CG73R1.7.3","CG73","Chronic Kidney Disease: National clinical guideline for early identification and management in adults in primary and secondary care","R80","Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care","R1.7.3"," Offer bisphosphonates if indicated for the prevention and treatment of osteoporosis in people  with stage 1, 2, 3a or 3b CKD.","Bisphosphonates for osteoporosis","","CG73S12","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
"","","","","","","","","","","","","","","","","","","","","","","",""
